Not true regarding waldenstorms macroglobulinemia is –
**Core Concept**
Waldenström's macroglobulinemia (WM) is a rare, chronic lymphoproliferative disorder characterized by the excessive production of IgM monoclonal antibodies. This leads to hyperviscosity syndrome, which is a hallmark feature of the disease.
**Why the Correct Answer is Right**
The correct answer is related to the pathophysiology of WM. WM is caused by the accumulation of IgM monoclonal antibodies, which can lead to hyperviscosity syndrome. This is due to the large size of IgM molecules, which can increase blood viscosity and lead to symptoms such as headaches, dizziness, and visual disturbances. The production of excess IgM antibodies also leads to a decrease in serum albumin, which can further exacerbate hyperviscosity syndrome.
**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because WM is indeed characterized by the excessive production of IgM monoclonal antibodies. This is a hallmark feature of the disease.
**Option B:** Incorrect because WM is not typically associated with the production of IgA or IgG monoclonal antibodies. While IgA and IgG monoclonal gammopathies can occur in other conditions, WM is specifically characterized by the production of IgM antibodies.
**Option C:** Incorrect because WM is not typically associated with the production of light chains. Light chain production is more commonly associated with conditions such as multiple myeloma or amyloidosis.
**Option D:** Incorrect because WM is not typically associated with the production of heavy chains only. WM is characterized by the production of complete IgM antibodies, which consist of heavy and light chains.
**Clinical Pearl / High-Yield Fact**
A key clinical feature of WM is the presence of hyperviscosity syndrome, which can lead to symptoms such as headaches, dizziness, and visual disturbances. This is due to the large size of IgM molecules, which can increase blood viscosity and lead to these symptoms.
**Correct Answer:** B. WM is not typically associated with the production of IgA or IgG monoclonal antibodies.